{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T13:29:51Z","timestamp":1782134991045,"version":"3.54.5"},"reference-count":70,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013711","name":"Bayer Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["canadianjournalofophthalmology.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.jcjo.2019.10.011","type":"journal-article","created":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T23:09:19Z","timestamp":1577142559000},"page":"199-211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Polypoidal choroidal vasculopathy in Canada"],"prefix":"10.1016","volume":"55","author":[{"given":"Wai-Ching","family":"Lam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Netan","family":"Choudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2019.10.011_bib0001","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/0002-9394(85)90682-8","article-title":"Multiple recurrent serous sanguineous retinal pigment epithelial detachments in black women","volume":"100","author":"Stern","year":"1985","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0002","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/00006982-199010010-00002","article-title":"The posterior uveal bleeding syndrome","volume":"10","author":"Kleiner","year":"1990","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00006982-199010010-00001","article-title":"Idiopathic polypoidal choroidal vasculopathy (IPCV)","volume":"10","author":"Yannuzzi","year":"1990","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0004","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.survophthal.2003.10.007","article-title":"Polypoidal choroidal vasculopathy","volume":"49","author":"Ciardella","year":"2004","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0005","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1097\/IAE.0000000000001872","article-title":"Prevalence of polypoidal choroidal vasculopathy in white patients with exudative age-related macular degeneration: systematic review and meta-analysis","volume":"38","author":"Lorentzen","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0006","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000355488","article-title":"Polypoidal choroidal vasculopathy: clinical features and genetic predisposition","volume":"231","author":"Honda","year":"2014","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0007","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1001\/archopht.117.11.1503","article-title":"Polypoidal choroidal vasculopathy and neovascularized age-related macular degeneration","volume":"117","author":"Yannuzzi","year":"1999","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0008","first-page":"650","article-title":"Polypoidal choroidal vasculopathy pattern in age-related macular degeneration: a clinicopathologic correlation","volume":"20","author":"Lafaut","year":"2000","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0009","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000439359","article-title":"Characteristics of neovascular age-related macular degeneration in Brazilian patients","volume":"234","author":"Pereira","year":"2015","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0010","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00417-003-0667-z","article-title":"Polypoidal choroidal vasculopathy in elderly Chinese patients","volume":"242","author":"Wen","year":"2004","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0011","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00417-007-0575-8","article-title":"Subtype lesions of neovascular age-related macular degeneration in Chinese patients","volume":"245","author":"Liu","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0012","doi-asserted-by":"crossref","first-page":"e487","DOI":"10.1111\/j.1755-3768.2011.02329.x","article-title":"Polypoidal choroidal vasculopathy in patients diagnosed with neovascular age-related macular degeneration in Denmark","volume":"90","author":"Ilginis","year":"2012","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0013","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ajo.2014.05.004","article-title":"Comparison of exudative age-related macular degeneration subtypes in Japanese and French Patients: multicenter diagnosis with multimodal imaging","volume":"158","author":"Coscas","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0014","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/sj.eye.6700706","article-title":"Polypoidal choroidal vasculopathy and exudative age-related macular degeneration in Greek population","volume":"18","author":"Ladas","year":"2004","journal-title":"Eye"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0015","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00006982-200104000-00004","article-title":"Polypoidal choroidal vasculopathy in Italy","volume":"21","author":"Scassellati-Sforzolini","year":"2001","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0016","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1001\/archopht.121.10.1392","article-title":"Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics","volume":"121","author":"Sho","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0017","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ajo.2007.03.047","article-title":"Clinical characteristics of exudative age-related macular degeneration in Japanese patients","volume":"144","author":"Maruko","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0018","doi-asserted-by":"crossref","first-page":"5914","DOI":"10.1167\/iovs.10-5554","article-title":"CFH and ARMS2 variations in age-related macular degeneration, polypoidal choroidal vasculopathy, and retinal angiomatous proliferation","volume":"51","author":"Hayashi","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0019","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.ophtha.2009.10.001","article-title":"Phenotype and genotype characteristics of age-related macular degeneration in a Japanese population","volume":"117","author":"Mori","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0020","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10384-007-0498-2","article-title":"Incidence and clinical patterns of polypoidal choroidal vasculopathy in Korean patients","volume":"52","author":"Byeon","year":"2008","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0021","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1080\/09286580902999413","article-title":"Age-related macular degeneration in a screened South Korean population: prevalence, risk factors, and subtypes","volume":"16","author":"Song","year":"2009","journal-title":"Ophthalmic Epidemiol"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0022","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3928\/15428877-20091030-07","article-title":"Polypoidal choroidal vasculopathy in Taiwanese patients","volume":"40","author":"Chang","year":"2009","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0023","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1136\/bjophthalmol-2016-310074","article-title":"Polypoidal choroidal vasculopathy: a common type of neovascular age-related macular degeneration in Caucasians","volume":"101","author":"Yadav","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0024","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jcjo.2017.02.014","article-title":"Age-related macular degeneration: is polypoidal choroidal vasculopathy recognized and treated?","volume":"52","author":"Chen","year":"2017","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0025","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1136\/bjophthalmol-2013-303444","article-title":"Polypoidal choroidal vasculopathy in Caucasian patients with presumed neovascular age-related macular degeneration and poor ranibizumab response","volume":"98","author":"Hatz","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0026","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaophthalmol.2017.4030","article-title":"Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial","volume":"135","author":"Koh","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0027","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1167\/iovs.18-24387","article-title":"Cytokine profiling in patients with exudative age-related macular degeneration and polypoidal choroidal vasculopathy","volume":"60","author":"Agrawal","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0028","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1167\/iovs.11-7913","article-title":"Associations of IL-23 with polypoidal choroidal vasculopathy","volume":"53","author":"Sasaki","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0029","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/jhg.2017.83","article-title":"Shared genetic variants for polypoidal choroidal vasculopathy and typical neovascular age-related macular degeneration in East Asians","volume":"62","author":"Fan","year":"2017","journal-title":"J Hum Genet"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0030","doi-asserted-by":"crossref","first-page":"14578","DOI":"10.1073\/pnas.1102853108","article-title":"Increased expression of multifunctional serine protease, HTRA1, in retinal pigment epithelium induces polypoidal choroidal vasculopathy in mice","volume":"108","author":"Jones","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0031","doi-asserted-by":"crossref","first-page":"6183","DOI":"10.1167\/iovs.09-4948","article-title":"Joint effect of cigarette smoking and CFH and LOC387715\/HTRA1 polymorphisms on polypoidal choroidal vasculopathy","volume":"51","author":"Nakanishi","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0032","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/eye.2014.226","article-title":"FPR1 interacts with CFH, HTRA1 and smoking in exudative age-related macular degeneration and polypoidal choroidal vasculopathy","volume":"28","author":"Liang","year":"2014","journal-title":"Eye"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0033","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12886-017-0631-z","article-title":"Association of ARMS2 genotype with response to anti-vascular endothelial growth factor treatment in polypoidal choroidal vasculopathy","volume":"17","author":"Park","year":"2017","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0034","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1136\/bjo.2003.032466","article-title":"Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy","volume":"88","author":"Matsuoka","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0035","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ajo.2005.10.012","article-title":"Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization","volume":"141","author":"Tong","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0036","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1097\/IAE.0000000000001665","article-title":"Polypoidal choroidal vasculopathy associated with central serous chorioretinopathy: pachychoroid spectrum of diseases","volume":"38","author":"Manayath","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0037","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/IAE.0000000000000794","article-title":"Distinguishing polypoidal choroidal vasculopathy from typical neovascular age-related macular degeneration based on spectral domain optical coherence tomography","volume":"36","author":"Liu","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0038","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.ajo.2014.08.025","article-title":"Sensitivity and specificity of spectral-domain optical coherence tomography in detecting idiopathic polypoidal choroidal vasculopathy","volume":"158","author":"De Salvo","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0039","doi-asserted-by":"crossref","first-page":"896","DOI":"10.4103\/ijo.IJO_1136_17","article-title":"Polypoidal choroidal vasculopathy: pearls in diagnosis and management","volume":"66","author":"Anantharaman","year":"2018","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0040","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1001\/jamaophthalmol.2017.4453","article-title":"The role of optical coherence tomography angiography in polypoidal choroidal vasculopathy","volume":"135","author":"Tan","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0041","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/eye.2016.232","article-title":"Comparison of indocyanine green angiography and optical coherence tomographic angiography in polypoidal choroidal vasculopathy","volume":"31","author":"Takayama","year":"2017","journal-title":"Eye"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0042","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/bjophthalmol-2016-309264","article-title":"Comparison of OCT angiography and indocyanine green angiographic findings with subtypes of polypoidal choroidal vasculopathy","volume":"101","author":"Tanaka","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0043","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.ophtha.2012.02.016","article-title":"Fundus autofluorescence in polypoidal choroidal vasculopathy","volume":"119","author":"Yamagishi","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0044","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4274\/tjo.54280","article-title":"Characteristics of fundus autofluorescence in active polypoidal choroidal vasculopathy","volume":"46","author":"\u00d6zta\u015f","year":"2016","journal-title":"Turk J Ophthalmol"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0045","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/bjophthalmol-2013-303739","article-title":"Changes in fundus autofluorescence after treatments for polypoidal choroidal vasculopathy","volume":"98","author":"Yamagishi","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0046","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ophtha.2017.11.019","article-title":"Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management","volume":"125","author":"Cheung","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0047","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1167\/iovs.16-21167","article-title":"Prevalence and risk factors for nonexudative neovascularization in fellow eyes of patients with unilateral age-related macular degeneration and polypoidal choroidal vasculopathy","volume":"58","author":"Yanagi","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0048","doi-asserted-by":"crossref","first-page":"e249","DOI":"10.3928\/23258160-20181203-15","article-title":"Characteristics of polypoidal choroidal vasculopathy evaluated by multspectral imaging","volume":"49","author":"Zhang","year":"2018","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0049","first-page":"359","article-title":"Polypoidal choroidal vasculopathy: an update on therapeutic approaches","volume":"8","author":"Wong","year":"2013","journal-title":"J Ophthalmic Vis Res"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0050","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0002-9394(02)01404-6","article-title":"Polypoidal choroidal vasculopathy: natural history","volume":"133","author":"Uyama","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0051","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1097\/IAE.0b013e31820d3f28","article-title":"Natural course and funduscopic findings of polypoidal choroidal vasculopathy in a Japanese population over 1 year of follow-up","volume":"31","author":"Bessho","year":"2011","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0052","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1136\/bjo.86.8.892","article-title":"Polypoidal choroidal vasculopathy in Chinese patients","volume":"86","author":"Kwok","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0053","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/bjo.2007.122283","article-title":"Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy","volume":"92","author":"Gomi","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0054","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/bjo.2008.150029","article-title":"Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6-month results","volume":"94","author":"Kokame","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0055","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/bjo.2007.135103","article-title":"Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy","volume":"92","author":"Lai","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0056","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ajo.2013.05.024","article-title":"Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results","volume":"156","author":"Oishi","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0057","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1136\/bjophthalmol-2018-312419","article-title":"Long-term results of photodynamic therapy or ranibizumab for polypoidal choroidal vasculopathy in LAPTOP study","volume":"103","author":"Miyamoto","year":"2019","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0058","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","article-title":"EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy","volume":"32","author":"Koh","year":"2012","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0059","series-title":"11th Asia-Pacific Vitreo-retina Society Congress 2017, December 8\u201310","article-title":"EVEREST 2 trial: 2-year results","author":"Koh","year":"2017"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0060","first-page":"1802","article-title":"One-year real-world outcomes of ranibizumab 0.5 mg treatment in Taiwanese patients with polypoidal choroidal vasculopathy: a subgroup analysis of the REAL study","volume":"11","author":"Chen","year":"2018","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0061","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00417-016-3489-5","article-title":"Efficacy of fixed-dosing aflibercept for treating polypoidal choroidal vasculopathy: 1-year results of the VAULT study","volume":"255","author":"Lee","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0062","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","article-title":"Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET Study: a randomized clinical trial","volume":"136","author":"Lee","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0063","series-title":"11th Asia-Pacific Vitreo-retina Society Congress 2017, December 8\u201310","article-title":"PLANET trial: 2-year results","author":"Ogura","year":"2017"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0064","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-015785","volume":"7","author":"Marques","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0065","series-title":"2019 Retina World Congress, March 21\u201324","author":"Marques","year":"2019"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0066","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s10384-018-0636-z","article-title":"The 24-month outcomes of intravitreal aflibercept combined with photodynamic therapy for polypoidal choroidal vasculopathy","volume":"63","author":"Nakai","year":"2019","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0067","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/s41598-018-37523-5","article-title":"Intravitreal aflibercept for active polypoidal choroidal vasculopathy without active polyps","volume":"9","author":"Lee","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0068","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1097\/IAE.0b013e318236e835","article-title":"Combined reduced fluence photodynamic therapy and intravitreal ranibizumab for polypoidal choroidal vasculopathy","volume":"32","author":"Ricci","year":"2012","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0069","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s10384-013-0234-z","article-title":"Two-year results of reduced-fluence photodynamic therapy combined with intravitreal ranibizumab for typical age-related macular degeneration and polypoidal choroidal vasculopathy","volume":"58","author":"Yoshida","year":"2013","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.jcjo.2019.10.011_bib0070","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/IAE.0000000000001614","article-title":"One-year results of half- versus standard-dose photodynamic therapy combined with ranibizumab for polypoidal choroidal vasculopathy","volume":"38","author":"Wong","year":"2018","journal-title":"Retina"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418219305551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418219305551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T20:09:42Z","timestamp":1757794182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418219305551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0008418219305551"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2019.10.011","relation":{},"ISSN":["0008-4182"],"issn-type":[{"value":"0008-4182","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polypoidal choroidal vasculopathy in Canada","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2019.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc. on behalf of Canadian Ophthalmological Society.","name":"copyright","label":"Copyright"}]}}